Oppenheimer Starts Agios Pharma (AGIO) at Perform

November 28, 2016 4:04 PM EST
Get Alerts AGIO Hot Sheet
Price: $49.58 +3.59%

Rating Summary:
    8 Buy, 7 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade AGIO Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Oppenheimer initiates coverage on Agios Pharma (NASDAQ: AGIO) with a Perform rating.

Analyst Leah Rush Cann commented, "We are initiating coverage of Agios Pharmaceuticals, a high-quality development-stage company working a new area of cancer research with novel experimental products. Agios has a superior management team. We rate Agios with a Perform rating, based on current valuation. We acknowledge meaningful upside potential exists and look forward to gaining better insights into these variables. We currently estimate Agios will launch its first drug, AG-221, in partnership with Celgene Corporation, in 2017 and its second drug, AG-120, by 2020."

For an analyst ratings summary and ratings history on Agios Pharma click here. For more ratings news on Agios Pharma click here.

Shares of Agios Pharma closed at $63.67 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, New Coverage

Add Your Comment